AAAAAA

   
Results: 1-8 |
Results: 8
PHASE-I TRIAL OF PACLITAXEL AND GEMCITABINE ADMINISTERED EVERY 2 WEEKS IN PATIENTS WITH REFRACTORY SOLID TUMORS
Authors: ROTHENBERG ML SHARMA A WEISS GR VILLALONACALERO MA ECKARDT JR AYLESWORTH C KRAYNAK MA RINALDI DA RODRIGUEZ GI BURRIS HA ECKHARDT SG STEPHENS CD FORRAL K NICOL SJ VONHOFF DD
Citation: Ml. Rothenberg et al., PHASE-I TRIAL OF PACLITAXEL AND GEMCITABINE ADMINISTERED EVERY 2 WEEKS IN PATIENTS WITH REFRACTORY SOLID TUMORS, Annals of oncology, 9(7), 1998, pp. 733-738
PHASE-II STUDY OF DOCETAXEL IN PATIENTS WITH UNRESECTABLE CHOLANGIOCARCINOMA
Authors: ROYCE M PAZDUR R RODRIGUEZ GM RINALDI DA PATT YZ BURRIS HA
Citation: M. Royce et al., PHASE-II STUDY OF DOCETAXEL IN PATIENTS WITH UNRESECTABLE CHOLANGIOCARCINOMA, Annals of oncology, 9, 1998, pp. 377-377
A BIOAVAILABILITY AND PHARMACOKINETIC STUDY OF ORAL AND INTRAVENOUS HYDROXYUREA
Authors: RODRIGUEZ GI KUHN JG WEISS GR HILSENBECK SG ECKARDT JR THURMAN A RINALDI DA HODGES S VONHOFF DD ROWINSKY EK
Citation: Gi. Rodriguez et al., A BIOAVAILABILITY AND PHARMACOKINETIC STUDY OF ORAL AND INTRAVENOUS HYDROXYUREA, Blood, 91(5), 1998, pp. 1533-1541
A RANDOMIZED PHASE-I STUDY OF ORAL ETOPOSIDE WITH OR WITHOUT GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR FOR THE TREATMENT OF PATIENTSWITH ADVANCED CANCER
Authors: WEISS GR SHAFFER DW DEMOOR C RINALDI DA RODRIGUEZ GI ECKARDT JR STEPHENS C VONHOFF DD
Citation: Gr. Weiss et al., A RANDOMIZED PHASE-I STUDY OF ORAL ETOPOSIDE WITH OR WITHOUT GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR FOR THE TREATMENT OF PATIENTSWITH ADVANCED CANCER, Anti-cancer drugs, 7(4), 1996, pp. 402-409
PHASE-II TRIAL OF IRINOTECAN IN PATIENTS WITH PROGRESSIVE OR RAPIDLY RECURRENT COLORECTAL-CANCER
Authors: ROTHENBERG ML ECKARDT JR KUHN JG BURRIS HA NELSON J HILSENBECK SG RODRIGUEZ GI THURMAN AM SMITH LS ECKHARDT SG WEISS GR ELFRING GL RINALDI DA SCHAAF LJ VONHOFF DD
Citation: Ml. Rothenberg et al., PHASE-II TRIAL OF IRINOTECAN IN PATIENTS WITH PROGRESSIVE OR RAPIDLY RECURRENT COLORECTAL-CANCER, Journal of clinical oncology, 14(4), 1996, pp. 1128-1135
INITIAL PHASE-I EVALUATION OF THE NOVEL THYMIDYLATE SYNTHASE INHIBITOR, LY231514, USING THE MODIFIED CONTINUAL REASSESSMENT METHOD FOR DOSE
Authors: RINALDI DA BURRIS HA DORR FA WOODWORTH JR KUHN JG ECKARDT JR RODRIGUEZ G CORSO SW FIELDS SM LANGLEY C CLARK G FARIES D LU P VONHOFF DD
Citation: Da. Rinaldi et al., INITIAL PHASE-I EVALUATION OF THE NOVEL THYMIDYLATE SYNTHASE INHIBITOR, LY231514, USING THE MODIFIED CONTINUAL REASSESSMENT METHOD FOR DOSE, Journal of clinical oncology, 13(11), 1995, pp. 2842-2850
PHASE-I AND PHARMACOKINETIC STUDIES OF TOPOTECAN ADMINISTERED AS A 72OR 120-H CONTINUOUS-INFUSION
Authors: BURRIS HA AWADA A KUHN JG ECKARDT JR COBB PW RINALDI DA FIELDS S SMITH L VONHOFF DD
Citation: Ha. Burris et al., PHASE-I AND PHARMACOKINETIC STUDIES OF TOPOTECAN ADMINISTERED AS A 72OR 120-H CONTINUOUS-INFUSION, Anti-cancer drugs, 5(4), 1994, pp. 394-402
A RANDOMIZED PHASE-I TRIAL OF CHRONIC ORAL ETOPOSIDE WITH OR WITHOUT GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR IN PATIENTS WITH ADVANCED MALIGNANCIES
Authors: SHAFFER DW SMITH LS BURRIS HA CLARK GM ECKARDT JR FIELDS SM WEISS GR RINALDI DA BOWEN KJ KUHN JG VONHOFF DD
Citation: Dw. Shaffer et al., A RANDOMIZED PHASE-I TRIAL OF CHRONIC ORAL ETOPOSIDE WITH OR WITHOUT GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR IN PATIENTS WITH ADVANCED MALIGNANCIES, Cancer research, 53(24), 1993, pp. 5929-5933
Risultati: 1-8 |